MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.

Further data analysis also identified a highly significant negative association between Palbociclib and HR repair pathway gene signature in A2780 ovarian cancer cells ( Fig. 2 a), with many HR repair pathway genes being strongly downregulated upon Palbociclib single-agent or in combination with Olaparib ( Fig. 2 b and Supplementary Fig. 4).

also in 132,142 other papers